{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Celldex+Therapeutics", "query": { "sponsor": "Celldex Therapeutics" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 68, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Celldex+Therapeutics&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T02:46:25.674Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05774184", "title": "A Study of CDX-0159 in Patients With Eosinophilic Esophagitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "barzolvolimab", "type": "BIOLOGICAL" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2023-06-01", "completion_date": "2026-01-23", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05774184" }, { "nct_id": "NCT03617328", "title": "Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "6MHP", "type": "BIOLOGICAL" }, { "name": "Montanide ISA-51", "type": "DRUG" }, { "name": "polyICLC", "type": "DRUG" }, { "name": "CDX-1127", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2018-11-13", "completion_date": "2024-01-19", "has_results": false, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 2, "location_summary": "Charlottesville, Virginia • Richmond, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03617328" }, { "nct_id": "NCT00648102", "title": "Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Bladder Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CDX-1307", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2006-01", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2010-07-26", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 3, "location_summary": "Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00648102" }, { "nct_id": "NCT06445023", "title": "A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "barzolvolimab", "type": "BIOLOGICAL" }, { "name": "Matching placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 963, "start_date": "2024-07-11", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445023" }, { "nct_id": "NCT01460134", "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Marginal Zone B Cell Lymphoma)", "Any T-cell Malignancy", "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma", "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer", "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)", "Burkett's Lymphoma", "Primary Lymphoma of the Central Nervous System" ], "interventions": [ { "name": "CDX-1127", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2011-10", "completion_date": "2017-10-16", "has_results": false, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01460134" }, { "nct_id": "NCT05231122", "title": "Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Clear Cell Adenocarcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian Serous Adenocarcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Serous Adenocarcinoma" ], "interventions": [ { "name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2024-03-12", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 2, "location_summary": "Buffalo, New York • Houston, Texas", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05231122" }, { "nct_id": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell", "Kidney Diseases", "Kidney Neoplasms", "Urogenital Neoplasms", "Urologic Diseases", "Urologic Neoplasms", "Neoplasms by Histologic Type", "Neoplasms", "Clear-cell Metastatic Renal Cell Carcinoma", "Melanoma", "Triple Negative Breast Cancer", "Bladder Cancer", "Head and Neck Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Combination of Varlilumab and Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-10", "completion_date": "2017-05-22", "has_results": false, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543645" }, { "nct_id": "NCT02302339", "title": "A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "glembatumumab vedotin", "type": "DRUG" }, { "name": "glembatumumab vedotin and varlilumab", "type": "DRUG" }, { "name": "glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)", "type": "DRUG" }, { "name": "glembatumumab vedotin and CDX-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2014-11", "completion_date": "2018-10-03", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302339" }, { "nct_id": "NCT03358719", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Blasts 30 Percent or Less of Bone Marrow Nucleated Cells", "Chronic Myelomonocytic Leukemia", "High Risk Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Refractory Anemia" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-03-27", "completion_date": "2021-08-25", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03358719" }, { "nct_id": "NCT07266402", "title": "A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Inducible Urticaria", "Cold Urticaria", "Cold-Induced Urticaria", "Symptomatic Dermographism" ], "interventions": [ { "name": "Barzolvolimab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2026-01-15", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-27T02:46:25.674Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Napa", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266402" } ] }